Clinical Trial

Vivatlac in Irritable Bowel Syndrome II (ViIBS2)

Name: Vivatlac in Irritable Bowel Syndrome II (ViIBS2) — clinical trial record (NCT07235215)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ViIBS2

Recruiting

View on ClinicalTrials.gov →

Summary

Multi-center,randomized, double-blind, placebo-controlled, 36 weeks trial investigating the effects of a nine-strain synbiotic (Vivatlac Synbiotikum) in IBS patients

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-11-14.

Status change: Not Yet Recruiting → Recruiting 2025-12-07

Trial Details

NCT Number	NCT07235215
Lead Sponsor	The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz
Conditions	Irritable Bowel Syndrome
Enrollment	200 participants
Start Date	2025-11-21
Primary Completion	2026-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2025-12-15